Olema Pharmaceuticals, Inc. $OLMA Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 56.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 217,023 shares of the company’s stock after selling 285,545 shares during the period. Pictet Asset Management Holding SA owned approximately 0.25% of Olema Pharmaceuticals worth $3,236,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in OLMA. SG Americas Securities LLC acquired a new stake in Olema Pharmaceuticals in the 4th quarter valued at approximately $1,735,000. Jennison Associates LLC bought a new position in shares of Olema Pharmaceuticals in the fourth quarter worth $24,100,000. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Olema Pharmaceuticals by 83.2% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 447,046 shares of the company’s stock valued at $11,176,000 after purchasing an additional 202,970 shares during the period. Kingdon Capital Management L.L.C. acquired a new position in shares of Olema Pharmaceuticals during the third quarter valued at $8,361,000. Finally, Tema Etfs LLC bought a new stake in shares of Olema Pharmaceuticals during the fourth quarter valued at about $1,113,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Performance

Shares of OLMA opened at $12.64 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. The firm’s 50 day moving average is $12.43 and its 200-day moving average is $18.77. Olema Pharmaceuticals, Inc. has a 12-month low of $4.37 and a 12-month high of $36.26. The stock has a market capitalization of $1.10 billion, a P/E ratio of -6.26 and a beta of 2.00.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). Equities research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

Analyst Ratings Changes

OLMA has been the subject of a number of recent analyst reports. Oppenheimer reiterated an “outperform” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Citigroup upped their price target on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Guggenheim decreased their price objective on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Wall Street Zen upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, April 27th. Finally, The Goldman Sachs Group dropped their target price on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Olema Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $44.10.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.